Skip to main content

Johnson & Johnson diluted shares

  • JNJ · NYSE
  • Healthcare
  • Pharmaceuticals
  • S&P 500
$285.75+0.79%Close 13 Nov 2026 · Market value $684.4B

Johnson & Johnson's diluted shares was 2.4B shares for fiscal year 2025 (the twelve months to 28 Dec 2025), unchanged from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 27 Sep 2026) it was 2.4B shares, up 0.8% from a year earlier.

From Johnson & Johnson's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 21 Oct 2026.

Fiscal 2025
2.4B
0.0%
Q3 FY2026
2.4B
+0.8% on a year
Growth over 9 years
−1.5%
a year, FY 2016–FY 2025

Diluted shares by fiscal year

2.8BFY 20162.7BFY 2017−1.6%2.7BFY 2018−0.6%2.7BFY 2019−1.6%2.7BFY 2020−0.5%2.7BFY 2021+0.1%2.7BFY 2022−0.4%2.6BFY 2023−3.9%2.4BFY 2024−5.1%2.4BFY 20250.0%

Change on the year before, under each year. From FY 2016 to FY 2025, Johnson & Johnson's diluted shares went from 2.8B shares to 2.4B shares, a compound annual change of −1.5%; the highest was 2.8B shares in FY 2016.

Johnson & Johnson diluted shares, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Diluted shares2.8B2.7B2.7B2.7B2.7B2.7B2.7B2.6B2.4B2.4B
Period end1 Jan 201731 Dec 201730 Dec 201829 Dec 20193 Jan 20212 Jan 20221 Jan 202331 Dec 202329 Dec 202428 Dec 2025

Diluted shares by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Johnson & Johnson diluted shares, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Diluted shares2.4B2.4B2.4B2.4B2.4B2.4B2.4B2.4B
Period end29 Dec 202430 Mar 202529 Jun 202528 Sep 202528 Dec 202529 Mar 202628 Jun 202627 Sep 2026

How diluted shares is measured

Diluted shares is the weighted average number of shares outstanding in the period, counting the shares that options, warrants and convertible securities could add; it is the count earnings per share is divided by. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Johnson & Johnson's other figures

Diluted shares of comparable companies

Everything on JNJ, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.